Security record · archived quarter
SOLV
Solventum Corporation · Healthcare · Medical - Instruments & Supplies
3Tracked holders
0Δ holders
555.50KShares held
$48.88MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 555.50K | $48.88M | n/a | n/a |
| Q2 2026 | 151 | +2 | 80.32M | $6.20B | +13 | −10 |
| Q1 2026 | 151 | -8 | 79.93M | $5.22B | +3 | −12 |
| Q4 2025 | 158 | +1 | 87.71M | $6.95B | +3 | −1 |
| Q3 2025 | 22 | +1 | 55.78M | $4.07B | +1 | −1 |
| Q2 2025 | 19 | 0 | 51.64M | $3.92B | +2 | −2 |
| Q1 2025 | 16 | -1 | 25.10M | $1.91B | +1 | −2 |
| Q4 2024 | 17 | -2 | 26.13M | $1.73B | +2 | −4 |
| Q3 2024 | 18 | +2 | 20.00M | $1.39B | +4 | −2 |
| Q2 2024 | 16 | n/a | 16.58M | $874.59M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 482.93K | +8278.4% | $42.57M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 46.27K | +17.5% | $4.00M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 26.30K | +5.2% | $2.31M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 873 holders, 128.07M shares, $8.18B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API